Addition of Ribociclib to Endocrine Therapy Improves Survival in Metastatic Breast Cancer
The phase II MAINTAIN trial evaluated the efficacy of adding ribociclib to endocrine therapy in patients with hormone receptor (HR)-positive, human epidermal growth factor...
“Practice-Changing” Results Seen With Targeted Therapy in HER2-Low Metastatic Breast Cancer
Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated significant survival benefit with trastuzumab deruxtecan...
These Factors Predict Survival in Patients With HER2-Positive Breast Cancer and Brain Metastases
Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting indicated that the following prognostic factors impact overall survival (OS) in...
Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer
Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, plus nab-paclitaxel showed promising anti-tumor activity in patients with HER2-positive...
